Dr Ronald Buckanovich discusses a novel class of drug aimed at treating ovarian cancer through concurrent targeting with c-Met and VEGF receptor tyrosine kinases. Research has shown that targeting VEGF receptors can be successful in the treatment of ovarian cancer; however such treatment is only effective for a limited time before cancer cells spread to other parts of the body. The addition of c-Met is intended to prevent these metastases and to limit the angiogenesis integral for tumour growth. Dr Buckanovich outlines the promising results of these agents in multi-centre trial assessing their use for the treatment of resistance ovarian and prostate cancer.